213 related articles for article (PubMed ID: 18672974)
1. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs.
Gordon IK; Ye F; Kent MS
Am J Vet Res; 2008 Aug; 69(8):1079-84. PubMed ID: 18672974
[TBL] [Abstract][Full Text] [Related]
2. mTOR and P70 S6 kinase expression in primary liver neoplasms.
Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M
Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
4. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
5. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma.
Brown RE; Zhang PL; Lun M; Zhu S; Pellitteri PK; Riefkohl W; Law A; Wood GC; Kennedy TL
Ann Clin Lab Sci; 2006; 36(3):273-82. PubMed ID: 16951268
[TBL] [Abstract][Full Text] [Related]
6. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J
Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492
[TBL] [Abstract][Full Text] [Related]
8. Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines.
Kent MS; Collins CJ; Ye F
Am J Vet Res; 2009 Feb; 70(2):263-9. PubMed ID: 19231960
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma.
Wan X; Mendoza A; Khanna C; Helman LJ
Cancer Res; 2005 Mar; 65(6):2406-11. PubMed ID: 15781656
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.
Faried LS; Faried A; Kanuma T; Nakazato T; Tamura T; Kuwano H; Minegishi T
Eur J Cancer; 2006 May; 42(7):934-47. PubMed ID: 16540312
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma.
Baba HA; Wohlschlaeger J; Cicinnati VR; Hilgard P; Lang H; Sotiropoulos GC; Takeda A; Beckebaum S; Schmitz KJ
Liver Int; 2009 Mar; 29(3):399-405. PubMed ID: 18492014
[TBL] [Abstract][Full Text] [Related]
12. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
Grozinsky-Glasberg S; Franchi G; Teng M; Leontiou CA; Ribeiro de Oliveira A; Dalino P; Salahuddin N; Korbonits M; Grossman AB
Neuroendocrinology; 2008; 87(3):168-81. PubMed ID: 18025810
[TBL] [Abstract][Full Text] [Related]
13. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y
Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108
[TBL] [Abstract][Full Text] [Related]
14. Estradiol attenuates the focal cerebral ischemic injury through mTOR/p70S6 kinase signaling pathway.
Koh PO; Cho JH; Won CK; Lee HJ; Sung JH; Kim MO
Neurosci Lett; 2008 May; 436(1):62-6. PubMed ID: 18378082
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors.
Drayer AL; Olthof SG; Vellenga E
Stem Cells; 2006 Jan; 24(1):105-14. PubMed ID: 16123382
[TBL] [Abstract][Full Text] [Related]
16. Melatonin prevents ischemic brain injury through activation of the mTOR/p70S6 kinase signaling pathway.
Koh PO
Neurosci Lett; 2008 Oct; 444(1):74-8. PubMed ID: 18721861
[TBL] [Abstract][Full Text] [Related]
17. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma.
Di Paolo S; Teutonico A; Ranieri E; Gesualdo L; Schena PF
Am J Kidney Dis; 2007 Mar; 49(3):462-70. PubMed ID: 17336708
[TBL] [Abstract][Full Text] [Related]
18. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling.
Wei C; Amos CI; Zhang N; Wang X; Rashid A; Walker CL; Behringer RR; Frazier ML
Clin Cancer Res; 2008 Feb; 14(4):1167-71. PubMed ID: 18281551
[TBL] [Abstract][Full Text] [Related]
19. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.
Dobashi Y; Suzuki S; Matsubara H; Kimura M; Endo S; Ooi A
Cancer; 2009 Jan; 115(1):107-18. PubMed ID: 19090006
[TBL] [Abstract][Full Text] [Related]
20. mTOR as a potential therapeutic target for treatment of keloids and excessive scars.
Ong CT; Khoo YT; Mukhopadhyay A; Do DV; Lim IJ; Aalami O; Phan TT
Exp Dermatol; 2007 May; 16(5):394-404. PubMed ID: 17437482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
